TRIALS STATUS

Ongoing/In Follow Up
June 19, 2019

ELI LILLY (I1F-MC-RHBX)

A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ixekizumab…
Read More
Ongoing/In Follow Up
June 19, 2019

ELI LILLY (I1F-MC-RHBY)

A Multicenter, Long-Term Extension Study of 104 Weeks, Including a Double-Blind, Placebo-Controlled 40-Week Randomized Withdrawal-Retreatment…
Read More
Ongoing/In Follow Up
June 19, 2019

AURINIA (AUR-VCS_2016-01)

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg…
Read More
Ongoing/In Follow Up
June 19, 2019

NOVARTIS (CQAW039A2315)

A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when…
Read More
Ongoing/In Follow Up
June 19, 2019

ENANTA PHARMACEUTICALS, INC. (EDP-305)

A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability,…
Read More
Ongoing/In Follow Up
June 19, 2019

AURINIA (AUR-VCS_2016-02)

A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg…
Read More
Active/Enrolling
June 19, 2019

ELI LILLY (I4V-MC-JAJA)

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Read More
Active/Enrolling
June 19, 2019

ELI LILLY (I8F-MC-GPGH)

A Randomized, Phase 3, Open-Label Trial Comparing the effect of LY3298176 versus Titrated Insulin Degludec…
Read More
Active/Enrolling
June 19, 2019

INTERCEPT PHARMACEUTICALS, INC. (747-304)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of…
Read More